Aurinia Pharmaceuticals – Analysts’ Recommendations and Stock Price Forecast (2024)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst’s rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock’s consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat’s consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat’s consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Consensus Rating
Moderate Buy
Based on 4 Analyst Ratings
Consensus Price Target
| High Forecast | $13.00 |
|---|---|
| Average Forecast | $10.00 |
| Low Forecast | $8.00 |
Get Aurinia Pharmaceuticals Upgrade and Downgrade Alerts
Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat’s FREE daily newsletter.
AUPH Analyst Recommendations By Month
The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
AUPH Price Targets by Month
The chart below shows how a company’s share price and consensus price target have changed over time. The dark blue line represents the company’s actual price. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table
Aurinia Pharmaceuticals Stock vs. The Competition
Recent Analyst Forecasts and Stock Ratings
Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 07:12 PM ET.
AUPH Frequently Asked Questions
-
What is Aurinia Pharmaceuticals’s stock forecast and purchase recommendation?
-
According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Aurinia Pharmaceuticals is $10.00, with a high forecast of $13.00 and a low forecast of $8.00. The consensus rating for Aurinia Pharmaceuticals stock is Moderate Buy based on the current 1 hold rating and 3 buy ratings for AUPH. Learn more on AUPH’s analyst rating history.
-
Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors?
-
Analysts like Aurinia Pharmaceuticals more than other “medical” companies. The consensus rating score for Aurinia Pharmaceuticals is 2.75 while the average consensus rating score for “medical” companies is 2.70. Learn more on how AUPH compares to other companies.
-
Does Aurinia Pharmaceuticals’s stock price have much upside?
-
According to analysts, Aurinia Pharmaceuticals’s stock has a predicted upside of 69.42% based on their 12-month stock forecasts.
![i’m-nervous,-too!-[part-2]](https://10xwealthreport.com/wp-content/uploads/2026/03/177042-im-nervous-too-part-2-1568x784.jpg)
